1.

Can Land Managers Control Japanese Knotweed? Lessons from Control Tests in Belgium

2.

Can Land Managers Control Japanese Knotweed? Lessons from Control Tests in Belgium

3.

Can Land Managers Control Japanese Knotweed? Lessons from Control Tests in Belgium

1.

Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium.

2.

Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium.

3.

Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium.

4.

Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium.

5.

Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium.

6.

Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium.

7.

Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium.

1.

Science Production in Germany, France, Belgium, and Luxembourg: Comparing the Contributions of Research Universities and Institutes to Science, Technology, Engineering, Mathematics...

2.

Science Production in Germany, France, Belgium, and Luxembourg: Comparing the Contributions of Research Universities and Institutes to Science, Technology, Engineering, Mathematics...

3.

Science Production in Germany, France, Belgium, and Luxembourg: Comparing the Contributions of Research Universities and Institutes to Science, Technology, Engineering, Mathematics...

4.

Science Production in Germany, France, Belgium, and Luxembourg: Comparing the Contributions of Research Universities and Institutes to Science, Technology, Engineering, Mathematics...

5.

Science Production in Germany, France, Belgium, and Luxembourg: Comparing the Contributions of Research Universities and Institutes to Science, Technology, Engineering, Mathematics...

6.

Science Production in Germany, France, Belgium, and Luxembourg: Comparing the Contributions of Research Universities and Institutes to Science, Technology, Engineering, Mathematics...

7.

Science Production in Germany, France, Belgium, and Luxembourg: Comparing the Contributions of Research Universities and Institutes to Science, Technology, Engineering, Mathematics...

8.

Science Production in Germany, France, Belgium, and Luxembourg: Comparing the Contributions of Research Universities and Institutes to Science, Technology, Engineering, Mathematics...

9.

Science Production in Germany, France, Belgium, and Luxembourg: Comparing the Contributions of Research Universities and Institutes to Science, Technology, Engineering, Mathematics...

1.

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

2.

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

3.

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

4.

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

5.

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

6.

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

7.

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

1.

Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study

2.

Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study

3.

Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study

4.

Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study

5.

Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study

6.

Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study

7.

Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study

1.

Real-world estimation of first- and second-line treatments for diffuse large B-cell lymphoma using health insurance data : a Belgian population-based study

2.

Real-world estimation of first- and second-line treatments for diffuse large B-cell lymphoma using health insurance data : a Belgian population-based study

3.

Real-world estimation of first- and second-line treatments for diffuse large B-cell lymphoma using health insurance data : a Belgian population-based study

1.

DataSheet_1_Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study.pdf

2.

DataSheet_1_Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study.pdf

3.

DataSheet_1_Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study.pdf

4.

DataSheet_1_Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study.pdf

5.

DataSheet_1_Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study.pdf

6.

DataSheet_1_Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study.pdf

7.

DataSheet_1_Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study.pdf

8.

DataSheet_1_Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study.pdf

9.

DataSheet_1_Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study.pdf

1.

Identificación, distribución y plantas hospederas de diez especies de agromyzidae (insecta: diptera), de interés agronómico en México

2.

Identificación, distribución y plantas hospederas de diez especies de agromyzidae (insecta: diptera), de interés agronómico en México

3.

Identificación, distribución y plantas hospederas de diez especies de agromyzidae (insecta: diptera), de interés agronómico en México

4.

Identificación, distribución y plantas hospederas de diez especies de agromyzidae (insecta: diptera), de interés agronómico en México

5.

Identificación, distribución y plantas hospederas de diez especies de agromyzidae (insecta: diptera), de interés agronómico en México

6.

Identificación, distribución y plantas hospederas de diez especies de agromyzidae (insecta: diptera), de interés agronómico en México

7.

Identificación, distribución y plantas hospederas de diez especies de agromyzidae (insecta: diptera), de interés agronómico en México

1.

Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen.

2.

Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen.

3.

Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen.

1.

Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries

2.

Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries

3.

Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries